Teams at the First People’s Hospital of Longquanyi District and Third Military Medical University develop a visualized XGBoost classifier that integrates STK1p, FPSA, FTPSA, and age to distinguish prostate carcinoma from benign hyperplasia, achieving an AUC of 0.965 and guiding biopsy decisions.
Key points
- Integration of serum thymidine kinase 1 (STK1p), free PSA (FPSA), FTPSA ratio, and age in an XGBoost model yields high discrimination (AUC 0.965).
- Model optimization via grid search (learning rate 0.1, max depth 5, subsample 0.8) and 10-fold cross-validation ensures robust performance.
- Visualization of 49 gradient-boosted decision trees and SHAP analysis enhances model interpretability for clinical biopsy decisions.
Why it matters: This interpretable XGBoost model significantly improves prebiopsy prostate cancer risk assessment, reducing unnecessary biopsies and optimizing early cancer detection strategies.
Q&A
- What is XGBoost and how does it work?
- What role does STK1p play as a biomarker?
- Why is AUC important in evaluating diagnostic models?